Reviews/Chronic Pain Pharmacotherapy/Opioids induce hyperalgesia
Opd · CPP-OPD-02 · v2
Several independent studies of chronic-pain patients on opioids find that these patients are more sensitive to experimental pain, such as cold or heat, than patients not on opioids [28][30][31][15]. Laboratory animal work describes a consistent biological pathway by which opioids could produce this heightened sensitivity [6][17][29][33]. However, the single randomised placebo-controlled trial, and the best powered human study, gave morphine for a month and found the expected loss of pain relief over time but no increase in pain sensitivity [13]. Most of the supportive human studies are snapshots that cannot separate an opioid effect from the pain condition itself or from the fact that sicker patients are more likely to be placed on opioids [28][30]. The sensitivity is also measured with experimental pain tests rather than by whether patients' own clinical pain worsens, and the effect depends on which test is used [30]. The panel landed between a confirmed and a dismissed verdict: a real, repeatedly observed phenomenon, but one whose causal and clinical reading is undercut by a negative trial, confounding, and indirect outcomes.
Multiple independent chronic-pain cohorts report that opioid-treated patients are hyperalgesic on quantitative sensory testing: community-dwelling adults show lower heat-pain slopes on opioids [28], methadone- and morphine-managed patients have shorter cold-pressor tolerance (18.1 and 19.7 seconds) than opioid-naive subjects (30.7 seconds) [30], all six patients in a one-month prospective study became hyperalgesic on the cold-pressor test [31], and low-dose opioid patients showed preoperative hyperalgesia on three sensory tests [15]. A subgroup with high negative affect showed a hyperalgesic pattern during oral opioid treatment [18]. Animal studies supply a coherent mechanism spanning spinal mTOR signalling [6], shared tolerance and chronification circuitry [17], Wnt5a-driven astrogliosis [29], and FLT3 signalling [33]. Against this, the one randomised, double-blind, placebo-controlled trial (N=103, one month of sustained-release morphine) found analgesic tolerance but did not demonstrate opioid-induced hyperalgesia [13]. The contested point: The evidence divides on whether a genuine opioid effect has been isolated: the convergent positive signal comes from cross-sectional and uncontrolled human designs plus animal mechanism, while the only experimental human test that could establish causation was negative [13]. The outcome itself is contested, since hyperalgesia appears on some sensory modalities but not others ([30]: present on cold-pressor, absent on electrical).
All 33 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Pain Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The best-powered and only randomised placebo-controlled human study [13] (N=103, 1 month sustained-release morphine) found tolerance but explicitly NOT opioid-induced hyperalgesia, directly contradicting the positive observational cohorts.
Confounding: chronic pain itself and disease progression produce central sensitization/hyperalgesia; the positive human studies [28][30] are cross-sectional and cannot separate an opioid effect from the underlying condition or from channelling of sicker patients onto opioids.
Where it remains uncertain. The best-powered and only randomised placebo-controlled study found tolerance but not opioid-induced hyperalgesia after one month [13], and the positive human studies are cross-sectional and use experimental surrogates [28][30].
Aleatory
The hyperalgesic pattern was confined to a high-negative-affect subgroup rather than being uniform [18], and the prospective positive signal rests on only six patients [31].
Epistemic
Only one randomised placebo-controlled human study exists [13] and it was negative; the positive studies are cross-sectional or uncontrolled [28][30], leaving the controlled evidence base thin.
Inferential
Hyperalgesia is measured by experimental sensory testing, not by worsening of patients' clinical pain, so the mapping to the claim is a step beyond the data [30][28].
The load-bearing papers from a corpus of 33, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Mechanistic (rat) basis for morphine-induced hyperalgesia; indirect to human clinical claim.
“mammalian target of rapamycin (mTOR), which governs most protein translation, was activated in rat spinal dorsal horn neurons after repeated intrathecal morphine injections”
Panel auditInternal validity: medium · scope of inference: Spinal mTOR/μ-opioid signalling in morphine tolerance and hyperalgesia in rats.Key limitations: preclinical · no chronic-pain model stated · species gap
Case-control QST evidence of preoperative hyperalgesia in opioid-treated chronic-pain patients.
“Chronic pain patients treated with low doses of opioid had hyperalgesia before surgery.”
Panel auditInternal validity: medium · scope of inference: Chronic pain patients on low-dose (mean 42 mg morphine-equivalent) long-term opioids before orthopaedic surgery.Key limitations: observational · low-dose only · confounding by chronic pain severity · modest n
Animal mechanism linking opioid adaptation and pain chronification; indirect.
“the transition from acute to chronic pain, and development of mu-opioid receptor tolerance and dependence may be linked by common cellular mechanisms in the primary afferent”
Panel auditInternal validity: medium · scope of inference: Shared primary-afferent mechanisms of opioid tolerance and chronic-pain transition in rats.Key limitations: preclinical · antagonist-precipitated hyperalgesia · mechanism not clinical outcome
Best-controlled human study (RCT, N=103) directly contradicts the claim.
“After 1 month of oral morphine therapy, patients with chronic low-back pain developed tolerance but not opioid-induced hyperalgesia.”
Panel auditInternal validity: high · scope of inference: One month of oral morphine in uncomplicated chronic non-radicular low back pain.Key limitations: only 1 month (short for 'long-term') · single indication · may miss later-onset OIH
4 of 33 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A real and repeatedly observed phenomenon whose causal 'induces' is undercut by a negative RCT, confounding and surrogate outcomes, holding it in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No positive randomised controlled trial. The causal 'induces' rests on observational data because the sole RCT found no hyperalgesia [13]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised, placebo-controlled trial of sustained opioid therapy with prespecified sensory-testing endpoints and a treatment duration beyond one month.
Open question: Does sustained oral opioid therapy cause increased pain sensitivity relative to placebo over periods longer than one month? Why it is still open: The only randomised placebo-controlled trial ran one month and found no hyperalgesia [13], while positive evidence is non-randomised [28][30].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19